Sudden Discontinuation of Hormone Medication 'Climodien' Leaves Patients Without Access

• Bayer has discontinued the global distribution of the hormone replacement medication 'Climodien' without prior public notice.
• The sudden withdrawal has left postmenopausal, intersex, and transgender patients facing treatment gaps and systemic confusion.
• Health authorities have advised patients to consult doctors for alternatives, yet a lack of proactive communication has caused significant harm.

Discontinuation and Causes

• Distribution ceased worldwide on July 1, following a decision by the manufacturer, Bayer.
• While Bayer has not publicly disclosed the reason, experts suggest low profit margins despite the drug holding a 14% market share.
• Industry data indicates nearly 20% of all medicines authorized by the EMA since 1995 have been withdrawn, often citing low demand or profitability.

Impact on Patients and Health Systems

• Patients reported discovering the discontinuation only when attempting to fill prescriptions at pharmacies, leading to emergency doctor visits.
• The abrupt cutoff creates immediate risks, as hormonal treatments are vital for physiological stability.
• Research from the 2024 'Transaludes' study indicates that nearly one in five transfeminine individuals has previously faced forced interruptions in hormone therapy.

Supply Chain Domino Effect and Demands

• Experts like gynecologist Rosa Almirall warn that forcing thousands of users to shift to alternative drugs like Progyluton may trigger secondary shortages for those medications.
• The activist group 'Plataforma Trans' is calling for the creation of a national protocol to guarantee the continuity of hormone treatments.
• Proposals include a Permanent Monitoring Board comprising public health authorities and trans organizations to manage supply risks and ensure equitable access.